Gannet BioChem has entered a development partnership with Serina Therapeutics to support the SER-252 program, an investigational therapy for advanced Parkinson's disease. The agreement combines Serina Therapeutics' proprietary POZ Platform technology with Gannet BioChem's expertise in process development, scale-up, and manufacturing support for complex therapeutic programs. This collaboration aims to advance SER-252 through clinical development following its recent clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA).

Nicholas Shackley, Chief Executive Officer of Gannet BioChem, stated that the partnership will contribute technical expertise to support the program through critical stages of growth. Steve Ledger, Chief Executive Officer of Serina Therapeutics, highlighted that Gannet BioChem's track record in complex polymer-based therapeutics complements their efforts to unlock the potential of their POZ Platform in neurology.

Key Partnership Details

The collaboration focuses on the development of SER-252, which targets advanced Parkinson's disease. The program has achieved a significant milestone with FDA IND clearance, allowing it to proceed into clinical trials.

Strategic Implications

This partnership expands Gannet BioChem's portfolio of development programs supporting biopharmaceutical companies from early-stage development through commercialization. The announcement follows Gannet BioChem's participation at the 2026 BIO International Convention, where the company engaged with industry partners to discuss emerging technologies and collaboration opportunities.

Gannet BioChem is a specialty contract development and manufacturing organization (CDMO) focused on activated polymers, including polyethylene glycol (PEG) reagents. Serina Therapeutics is a clinical-stage biotechnology company developing drug product candidates for neurological diseases using its POZ Platform technology.

Kothari Fermentation & Biochem Limited has opened a special window to facilitate the transfer and dematerialisation of physical shares held by its shareholders. This initiative is pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, which mandates that listed entities issue securities only in dematerialised form.

The company disclosed this development through advertisements published on June 05, 2026, in the Financial Express (English) and Jansatta (Regional language). This communication serves as a second reminder to the exchange, following an initial disclosure dated February 7, 2026, and a first reminder dated April 6, 2026.

The special window provides an opportunity for shareholders holding physical share certificates to convert them into electronic form. This move aligns with the regulatory framework aimed at ensuring a fully dematerialised trading environment and reducing risks associated with physical securities.

The following table outlines the key details of the regulatory compliance:

Shareholders are advised to utilize this facility to update their holdings. The submission to the BSE Limited was made by Shivani, Company Secretary & Compliance Officer, confirming the completion of the required newspaper publications.